EGFR and non-small cell lung carcinoma: Osimertinib was granted accelerated approval by the US Food and Drug Administration (FDA) in 2015 for the treatment of patients with advanced and metastatic EGFR T790M–mutant NSCLC who experienced disease progression on prior TKI therapy.